Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Managing conflicts of interest: A survival guide for biotechs

Article Abstract:

Federal law and other applicable rules are described to provide guidelines to overcome possible conflicts that might arise specifically from the relationships between life science companies and the clinicians they hire as investigators or participants in their trials. As with other legal and ethical issues confronting life science companies, it is critical for the company to understand the relevant law, gather relevant facts about the rules governing their particular situations and take necessary action.

Author: Price, Elizabeth, Werner, Michael J.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
Life sciences research

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


FDA and EMEA pool scientific advice

Article Abstract:

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) on September 2004, announced a one-year pilot program that would start in January 2005 permitting companies to seek parallel scientific advice on testing their products from both the agencies simultaneously. The pilot program would allow the companies to discuss and get the input from both the agencies regarding various fundamental issues like trial duration and primary endpoints.

Author: Katsnelson, Alla
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
Europe, Product development, Biological products industry, Drug approval

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Cautious welcome for FDA pharmacogenomics guidance

Article Abstract:

The final version of the US Food and Drug Administration's (FDA) Guidance for Industry was issued by FDA on 22 March 2005 on the submission of pharmacogenomics data. Brain Spear, director of pharmacogenomics at Abbott Laboratories in Abott Park state that the document's main impact is on reassuring companies that are conducting early-stage pharmacogenomic experiments will not bring negative regulatory consequences.

Author: Katsnelson, Alla
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
Pharmacogenetics, Pharmacogenomics

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Laws, regulations and rules, Biotechnology industry, Biotechnology industries, Government regulation
Similar abstracts:
  • Abstracts: Japan-China merger puts growth in East Asia first. Japanese giants renew interest in industrial biotech. Japanese firms broaden investment focus to early biotech
  • Abstracts: Computational prediction of proteotypic peptides for quantitative proteomics. Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor
  • Abstracts: Iran nuclear 'countdown' demands U.S. response-author. Bunker buster study survives close House vote. Administartion faces awkward position on Iran nukes, expert says
  • Abstracts: Madelaine Chocolate Novelties Candies. Splurge! Without The Carbs Candies
  • Abstracts: Canali Aftershave Lotion; Aftershave Balm. Canali Body Shampoo for Men
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.